Clinical Trials Search Results
Clinical trials provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.
A study to evaluate the clinical validity of a ctDNA-based MRD test designed to detect breast cancer progression or recurrence following surgery
MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer
Sponsor: Myriad Genetics
A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Sponsor: Regeneron Pharmaceuticals
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (Including Cervical, Urothelial, Ovarian, and Prostate Cancer)
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Sponsor: Klus Pharma Inc
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Sponsor: TiumBio Co, Ltd
A Study to Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor: Shanghai Henlius Biotech
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
A Phase 1, Multicenter, Open-label, First-in-human Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Sponsor: MediLink Therapeutics
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
Sponsor: iTeos Belgium SA
A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Sponsor: Shanghai Henlius Biotech
D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
The aim of this study is to learn more about the drug called benralizumab (Fasenra®) and to better understand how it works in the treatment of severe eosinophilic asthma.
Identification of Immunological Host Defense Mechanisms Against Nontuberculous Mycobacteria: A pilot Study to Measure Immune Response in Patients with and without Nontuberculous Mycobacterial (NTM) Infection
The purpose of this study is to gain insight into the factors that contribute to protection against NTM. It is hoped that information collected from this study will lead to new treatment options to improve outcomes of patients infected with NTM.
IRB #: 1085
Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
The purpose of this study is to compare the effectiveness and tolerability of a 2-study drug treatment regimen and a 3-study drug treatment regimen in subjects who have recently been diagnosed with pulmonary (lung) disease caused by Mycobacterium avium complex (MAC).
The purpose of the program is to identify a group of people who are interested in receiving information about research studies focused on bronchiectasis and/or non-tuberculosis mycobacteria (NTM) and possibly participating in these research studies.
Sponsor: COPD Foundation
The goal of the Patient Registry is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Panbela Therapeutics
Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Sponsor: Epizyme, Inc
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor: Karyopharm Therapeutics Inc
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Daiichi Sankyo, Inc
RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.
Sponsor: Renovion, Inc.
MACrO2 – A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with treatment-Refractory Mycobacterium avium Complex Lung Disease – Protocol EBO-301
Sponsor: AN2 Therapeutics